Copyright ©2016 MBD                                 Specification and product names are trademarks or trade names of their respective companies or organizations.


Our company was established in 2015 to provide a platform for predicting the efficacy and toxicity of drugs based on original three-dimensional cell cultures.

3D cell chip with hydrogel-based pillar structure is a technology that can overcome the problems of conventional two-dimensional cell culture and has been proven by the domestic and foreign pharmaceutical companies, hospitals and research institutes for superior technology.

In addition, we are establishing a base for providing optimal anti-cancer drugs using patient-derived cancer cells for the successful personalized medicine for cancer treatment.

It will give hope to the patients, reduce the economic cost to the family, and secure the market competitiveness by shortening the development time for the company that develops new drugs.

Therefore, MBD will grow into a global comprehensive biotechnology company based on steady research and development and honest business ethics.

Mission and Vision
Global No.1 comprehensive biotechnology company of patient personalized treatment
MBD Co., Ltd. is committed to providing customer satisfaction with a new paradigm for drug development and personalized cancer treatment

• A three-dimensional cell-based, high accuracy, easy-to-use, cost-effective provides total efficacy and toxicity assessment solution

• Automated analytical equipment and consumables manufacture and sale to Medical & Bio labs for pharmaceutical companies, hospitals, universities and research institutes

• New opportunities for rapid and inexpensive assessment of drug efficacy at very early phases of clinical study for individual cancer patients

Our History
+ Scientific Advisories
Sunghoon Kim

+ Professor, Pharmaceutics, Seoul National University (SNU)

+ Head, Medicinal Bioconvergence Research Center (BIOCON)

+ Senior Scientist, Cubist Pharmaceuticals, USA

+ Visiting proferssor, Scripps Research Institute, USA

+ Advisors to National Drug Screening Center, China

+ Postdoctoral fellow, MIT, USA

+ PhD, Brown University, USA

Yong-Jun Kwon

+ Head of High Content Screening and Technology Development, Ksilink, France

+ Principal Scientist, Institute for Refractory Cancer Research, Samsung Medical Center

+ Research professor in Sungkyunkwan University School of Medicine, Samsung Medical Center

+ Head of Discovery Biology Group & Screening Platform Technology Group, Institut Pasteur Korea 

+ PhD, in Functional Genomics, Yonsei University 

Moo-Yeal Lee

+ Professor, Department of Chemical & Biological Engineering, Cleveland State University, Cleveland, OH, USA

+ Co-founder and CTO, 3D MicroArray Inc, USA

+ Adjunct Faculty, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

+ Lead/Senior Scientist, Solidus Bioscience, Inc., San Francisco, CA, USA

+ Postdoctoral fellow, Rensselaer Polytechnic Institute (RPI), NY, USA

+ PhD, Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST)

+ Business Development & Licensing Advisories
+ Collaborators
Samsung Medical Center, Institute for Refractory Cancer Research
Seoul National University, Medicinal Bioconvergence Research Center
Korea Institute of Toxicology
The Catholic University of Korea
Eli Lilly
Cleveland State University
University of California, Berkeley
Rensselaer Polytechnic Institute
Need more details? Contact us
We are here to assist. Contact us by phone, email or via our Social Media channels.